reason report
ahead covid
result ahead street well ahead expect
uncertainti post revenu prior
guid rang beat driven strong
sequenc consum growth off-set disrupt final week
quarter covid mostli impact instrument sale sequenc
lab especi diagnost lab usual order month suppli
sequenc consum trend could acceler larger
order lead stock prior sequenc consum
gener shelf life month suggest bounc back
consum might slightli less custom return back
lab start place order still expect dx custom order
robustli vs academ one upon return continu maintain
view experi signific impact
potenti custom stock ahead disrupt
could respons strong though await detail
manag team call recogn potenti
custom stock sequenc consum ahead covid
disrupt drive sequenc consum even higher see
could potenti cap upsid seq consum
custom return lab ultim impact
expect appetit new instrument purchas remain
mute even custom return back lab see new
instrument purchas includ novaseq nextseq broader
capit equip purchas remain mute lab start see
demand growth across custom rich academ fund
environ limit appetit believ could last well
see disrupt drive behavior
univers institut diagnost lab biopharma custom
conserv cash near term thu push instrument purchas
believ bound impact instrument purchas
net debt total capit
price-to-earnings lt ep growth
life scienc tool diagnost
compani inform svb leerink llc research
revenu mm ep exclud charg amort intang
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
year price history/av daili volume mil
pop-seq uk biobank project stay ahead schedul
sequenc pull-thru lower significantli amid covid
weekend also spoke medacorp kol regard ukbb uk
biobank project lab run ahead schedul
project complet genom march activ slow
come week uk government implement stay at-hom measur
current lab focus viral genom viral-human
rna/dna sequenc novaseq oper flowcel
mostli vs prior flowcel thu deliv almost third prior
pull-thru larg custom expect lab remain
mode next month covid worri pass uk
novaseq return back sequenc human genom part
pop-seq project time see revenu off-set
whole genom patient studi provid insight
signific variat diseas sever among infect popul
lever consum longer term see lever
consum clinic sequenc longer term ilmn
sequenc consum revenu split research
appli clinic research appli volum larg
shape length univers shutdown pace ramp-up
clinic rev half attribut oncolog overal seq
consum would character safe
half split reproduct health genet
diseas although may off-set increment
work patient unabl access hospit clinic volum
updat model includ revenu slightli tweak
estim rest year reflect today
announc revenu remaind year
tweak slightli new sequenc consum revenu growth
prior new organ revenu estim
prior ep prior
guidanc suspend confer call set
rate share outperform price target believ
major popul develop emerg world like touch one
genet test lifetim creat massiv market believ stand
benefit market compani see sequenc market
number sampl depth coverag expand dramat next year
novaseq upcom instrument drive signific reduct sequenc cost
earlier hiseq current novaseq flow cell
like futur set path genom price beyond
high throughput platform also continu drive double-digit growth desktop system
includ nextseq essenti key high growth market includ non-invas
prenat test nipt faster turn-around sampl oncolog continu
domin sequenc market world-wide life scienc genet test reproduct health
oncolog market share revenu market share sequenc unit
believ ilmn market share accuraci throughput enterpris level servic product
factor continu keep custom bound despit custom
consid higher price still direct strong competit sight somewhat
unbound market believ continu domin next-gen sequenc keep
drive sequenc cost lower lead elast demand sampl deeper
share current trade price-to-earnings consensu ep averag
multipl view potenti unbound market opportun major
popul develop develop world like touch sequenc
form test next year use dcf analysi beta long-
term growth rate wacc arriv price target believ
remain strong forc sequenc market see revenu growth continu
outer year addit believ long-term growth rate conserv
estim given sequenc repres somewhat unbound market opportun
view still applic continu explor beyond current one
margin profil would face downward pressur given new entrant innov competitor
understand domin market share genom sequenc industri
tmo ion torrent main competit believ major
competit near term product instal expens
competitor given near-monopoli howev custom balk price major
innov develop futur expect gross oper margin
declin given competit note occupi market share industri
instal base due expens equip instal highlight
import price consum elast product
affect reimburs decis medicar although posit cash
flow critic mass instal base demand genom test product
affect reimburs rate declin reimburs like lead lower demand
product activ turn would affect usag consum product
seen effect reimburs rate chang peer genom test industri
drop would certainli impact revenu believ ilmn growth profil could
significantli slow reimburs rate lower would like contribut
regul fda could major impact revenu well current
sell diagnost product laboratori consid laboratori develop test
ldt fda yet regul ldt due prolifer product
industri fda may revers cours regul ldt addit product requir
fda approv intend use diagnosi diseas
expand product purpos subject greater test complianc
standard increas oper expens believ addit regul
ilmn ldt research-us product would result risk estim
high level capit expenditur involv oper mean disrupt capital-expenditure
spend could lead slower growth level capital-expenditure need launch support new
product import growth slight delay instrument shipment
consum could caus guidanc miss miss guidanc close
one less hiseqx system anticip given small room error
one deal leverag capital-expenditure maintain oper risk
disrupt and/or govern mandat shutdown could persist longer
expect impact instrument order consum usag custom demand may
impact short-to-medium term result pandem
good sold
interest expens incom
add net incom attribut non-control interest
net incom attribut
sg sale
 sale
oper expens sale
sg revenu
 revenu
compani report svb leerink estim
 depreci alreadi ex amort
